ANAPTYSBIO, INC. Fair Value Adjustment of Warrants
ANAPTYSBIO, INC. (ANAB) reported Fair Value Adjustment of Warrants of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-02.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2020-03-02
- ANAPTYSBIO, INC. fair value adjustment of warrants for the quarter ending 2018-12-31 was $0.00.
- ANAPTYSBIO, INC. fair value adjustment of warrants for the quarter ending 2018-09-30 was $0.00.
- ANAPTYSBIO, INC. fair value adjustment of warrants for the quarter ending 2018-06-30 was $0.00.
- ANAPTYSBIO, INC. fair value adjustment of warrants for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. fair value adjustment of warrants for fiscal 2019 was $0.00.
- ANAPTYSBIO, INC. fair value adjustment of warrants for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- ANAPTYSBIO, INC. fair value adjustment of warrants for fiscal 2017 was $1.37M, a 80.69% increase from fiscal 2016.
- ANAPTYSBIO, INC. fair value adjustment of warrants for fiscal 2016 was $756.00K, a 40.80% decline from fiscal 2015.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-02 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-07 | $0.00 10-Q · filed 2018-08-07 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-08 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $1.37M 10-K · filed 2020-03-02 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $1.37M 10-Q · filed 2018-11-08 | $2.46M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-07 | $1.37M 10-Q · filed 2018-08-07 | $2.46M derived: sum of 3 quarters · filed 2019-02-28 | $2.50M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $1.37M 10-Q · filed 2018-05-08 | $2.46M derived: sum of 2 quarters · filed 2019-02-28 | $2.50M derived: sum of 3 quarters · filed 2019-02-28 | $2.50M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $1.14M derived: sum of 2 quarters · filed 2019-02-28 | $1.14M derived: sum of 3 quarters · filed 2019-02-28 | $756.00K 10-K · filed 2019-02-28 |
| 2016-09-30 | $47.00K 10-Q · filed 2017-11-07 | $44.00K derived: sum of 2 quarters · filed 2017-11-07 | -$335.00K 10-Q · filed 2017-11-07 | |
| 2016-06-30 | -$3.00K 10-Q · filed 2017-08-10 | -$382.00K 10-Q · filed 2017-08-10 | ||
| 2016-03-31 | -$379.00K 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | $1.28M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |